Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice.
If you are looking for guidance based on this study's results: IFM_05-May 2022
Lenalidomide was the primary drug used for maintenance in this study. Key Findings: Research published around May 2022 explored the impact
The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo. IFM_05-May 2022